Drug intelligence / Profile preview

prednisolone + methylprednisolone + deflazacort

Development stage: Unknown
Lead developer: Marathon Pharmaceuticals
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

This is a combination of three synthetic glucocorticoids (prednisolone, methylprednisolone, and deflazacort) that have anti-inflammatory and immunosuppressive properties. Each drug works by decreasing inflammation and modifying the body's immune response. Methylprednisolone is a derivative of prednisolone, while deflazacort is an oxazoline derivative of prednisolone. These corticosteroids have different potencies and conversion ratios between them.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on prednisolone + methylprednisolone + deflazacort.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednisolone + methylprednisolone + deflazacort.

Explore the full profile